688185 Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$70.37 |
52 Week High | HK$85.58 |
52 Week Low | HK$37.12 |
Beta | 0.46 |
11 Month Change | 19.01% |
3 Month Change | 79.93% |
1 Year Change | -8.22% |
33 Year Change | -74.41% |
5 Year Change | n/a |
Change since IPO | -82.10% |
Recent News & Updates
Recent updates
Shareholder Returns
688185 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 5.8% | 1.1% | 2.2% |
1Y | -8.2% | -16.9% | 10.2% |
Return vs Industry: 688185 exceeded the CN Biotechs industry which returned -17.7% over the past year.
Return vs Market: 688185 underperformed the CN Market which returned 8.9% over the past year.
Price Volatility
688185 volatility | |
---|---|
688185 Average Weekly Movement | 12.1% |
Biotechs Industry Average Movement | 8.9% |
Market Average Movement | 8.5% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688185's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688185's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,149 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
688185 fundamental statistics | |
---|---|
Market cap | CN¥12.16b |
Earnings (TTM) | -CN¥720.11m |
Revenue (TTM) | CN¥748.53m |
10.2x
P/S Ratio-10.6x
P/E RatioIs 688185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688185 income statement (TTM) | |
---|---|
Revenue | CN¥748.53m |
Cost of Revenue | CN¥774.40m |
Gross Profit | -CN¥25.87m |
Other Expenses | CN¥694.25m |
Earnings | -CN¥720.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.91 |
Gross Margin | -3.46% |
Net Profit Margin | -96.20% |
Debt/Equity Ratio | 41.3% |
How did 688185 perform over the long term?
See historical performance and comparison